CWM
AEGR

Cabot Wealth Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Cabot Wealth Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-51,959
Closed -$2.4M – 159
2014
Q1 		$2.4M Sell
51,959
-10,028
-16% -$588K 0.63% 77
2013
Q4 		$4.4M Buy
61,987
+14,351
+30% +$1.1M 1.15% 26
2013
Q3 		$4.08M Buy
47,636
+120
+0.3% +$10.2K 1.22% 17
2013
Q2 		$3.01M Buy
+47,516
New +$2.52M 1.04% 26

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cabot Wealth Management's AEGR Position: Q2 2014 in Review

Cabot Wealth Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 51,959 shares — an estimated $2.4M sold.

Cabot Wealth Management first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $4.4M in Q4 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Cabot Wealth Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Cabot Wealth Management sold 51,959 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $2.4M.
  • Cabot Wealth Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Cabot Wealth Management's Aegerion Pharmaceuticals position peaked at $4.4M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Cabot Wealth Management's 13F filing for Q2 2014, filed 28 Jul 2014.